RxDoctor Payments DataLook up a doctor →

Laura Kimball Ravari, MD

Endocrinology, Diabetes & Metabolism · Bossier City, LANPI 1861437543

Payments from drug & device makers

$164,537in general payments, 2019–2025

Across 1,047 payments — averaging $157.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$117K
  • Sanofi-aventis U.S. LLC$14K
  • AbbVie$12K
  • Corcept Therapeutics$9K
  • Medtronic$2K
  • Lilly USA, LLC$1K
  • plus $9K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk238$116,567
Sanofi-aventis U.S. LLC73$14,326
AbbVie41$11,524
Corcept Therapeutics82$9,358
Medtronic(2 entities)75$2,245
Lilly USA, LLC83$1,337
Amgen(2 entities)50$1,205
AstraZeneca(2 entities)33$703
Dexcom, Inc.35$659
Amarin Pharma, Inc.42$653
Xeris Pharmaceuticals, Inc.33$578
Insulet Corporation22$462
Abbott19$429
Antares Pharma, Inc.19$372
Recordati_rare_diseases_inc.16$360
Esperion Therapeutics, Inc.5$296
Tandem Diabetes Care, Inc.13$267
Bayer10$265
Boehringer Ingelheim18$259
Currax Pharmaceuticals LLC17$243
Merck16$217
Shire North American Group Inc6$196
Radius Health, Inc.8$168
Pfizer9$156
IBSA Pharma Inc.8$147
Lundbeck LLC1$125
Kowa Pharmaceuticals America, Inc.8$116
Acella Pharmaceuticals, LLC6$107
Ascendis Pharma Endocrinology Inc5$98
Nevro Corp.5$95
Johnson & Johnson6$90
Chiasma, Inc.1$85
GRT US Holding, Inc.5$79
Regeneron Healthcare Solutions, Inc.3$60
EUSA Pharma (US) LLC3$58
Kyowa Kirin, Inc.3$55
Sequel Med Tech, LLC3$55
Averitas Pharma Inc.2$51
Neurocrine Biosciences, Inc.2$50
Ultragenyx Pharmaceutical Inc.3$49
Ipsen Biopharmaceuticals, Inc2$42
Amryt Pharma Holdings Ltd2$40
Clarus Therapeutics Inc.2$32
Madrigal Pharmaceuticals2$32
Cequr Corporation1$30
Halozyme Inc1$25
Boston Scientific1$21
BETA Bionics, Inc.1$20
Chiesi USA, Inc.1$19
Takeda Pharmaceuticals U.S.A., Inc.1$19
OPKO Pharmaceuticals, LLC1$17
Rhythm Pharmaceuticals, Inc.1$17
Vifor Pharma, Inc.1$17
Melinta Therapeutics, LLC1$14
GSK1$14
Zealand Pharma US, Inc.1$13

How this compares

$164,537 in reported general payments places this provider in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

See all endocrinology, diabetes & metabolism providers in Louisiana →

Medicare billing

Part B allowed, 2024
$95,031
Medicare patients
476
Services billed
1,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Bossier City

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →